Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Combining lenalidomide with erythropoiesis stimulating agents: a party of one
Leukemia, Published online: 15 February 2024; doi:10.1038/s41375-024-02176-zCombining lenalidomide with erythropoiesis stimulating agents: a party of one (Source: Leukemia)
Source: Leukemia - February 15, 2024 Category: Hematology Authors: Namrata S. Chandhok Mikkael A. Sekeres Source Type: research
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
We present a frontline alternative for treatment- na ïve (TN) CLL/SLL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 12, 2024 Category: Hematology Authors: Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A. Kharfan-Dabaja Tags: Original Study Source Type: research
Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
Australas J Dermatol. 2024 Feb 7. doi: 10.1111/ajd.14218. Online ahead of print.NO ABSTRACTPMID:38326991 | DOI:10.1111/ajd.14218 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - February 8, 2024 Category: Dermatology Authors: Luca Bettolini Stefano Bighetti Vincenzo Maione Iacopo Ghini Diego Segala Piergiacomo Calzavara-Pinton Source Type: research
Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma —a single-center retrospective study
(Source: Neurological Sciences)
Source: Neurological Sciences - February 7, 2024 Category: Neurology Source Type: research
Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase
Eur J Med Chem. 2024 Jan 29;267:116167. doi: 10.1016/j.ejmech.2024.116167. Online ahead of print.ABSTRACTThe Ataxia telangiectasia and RAD3-related (ATR) kinase is a key regulator of DNA replication stress responses and DNA-damage checkpoints. Several potent and selective ATR inhibitors are reported and four of them are currently in clinical trials in combination with radio- or chemotherapy. Based on the idea of degrading target proteins rather than inhibiting them, we designed, synthesized and biologically characterized a library of ATR-targeted proteolysis targeting chimera (PROTACs). Among the synthesized compounds, the...
Source: European Journal of Medicinal Chemistry - February 3, 2024 Category: Chemistry Authors: Abdallah M Alfayomy Ramy Ashry Anita G Kansy Anne-Christin Sarnow Frank Erdmann Matthias Schmidt Oliver H Kr ämer Wolfgang Sippl Source Type: research
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
ConclusionsOutcomes in patients with R/R DLBCL treated with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents remain poor, especially for those with challenging-to-treat R/R DLBCL. These findings underscore the unmet need for new, safe, and effective therapies, especially for challenging-to-treat R/R DLBCL populations. (Source: Advances in Therapy)
Source: Advances in Therapy - February 2, 2024 Category: Drugs & Pharmacology Source Type: research
Isatuximab-pomalidomide-dexamethasone < em > versus < /em > pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.284325. Online ahead of print.ABSTRACTThe primary and pre-specified updated analyses of ICARIA-MM (NCT02990338) demonstrated improved progression-free survival and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase 3 study included patients who had received and failed ≥2 previous therapies, including lenalidomide and a proteasome i...
Source: Haematologica - February 1, 2024 Category: Hematology Authors: Paul G Richardson Aurore Perrot Jesus San Miguel Meral Beksac Ivan Spicka Xavier Leleu Fredrik Schjesvold Philippe Moreau Meletios A Dimopoulos Shang-Yi Huang Jiri Minarik Michele Cavo H Miles Prince Sandrine Mac é Rick Zhang Franck Dubin Mony Chenda Mor Source Type: research
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
ConclusionsOver 3 years, the estimated cumulative per patient cost of mosunetuzumab is lower than most available newer therapies, resulting in a small increase in the budget after its formulary adoption for the treatment of relapsed or refractory follicular lymphoma. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 1, 2024 Category: Health Management Source Type: research
